Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis

ABSTRACT

Background

Multi-criteria decision analysis (MCDA) was proposed to surmount arbitrary clinical decisions in the field of biological therapies for psoriatic patients. At the same time, MCDA may further highlight the potential of bimekizumab for the treatment of moderate-to-severe psoriasis, compared to placebo, adalimumab, ustekinumab, secukinumab, and even ixekizumab and risankizumab.

Research design and methods

The EVIDEM framework was adapted to reflect relevant criteria for the assessment. Estimated values were obtained by means of an additive linear model combining weights and scores assigned by a multidisciplinary committee of 12 experts. Consistency and replicability were evaluated through an alternative weighting method and a re-test.

Results

Bimekizumab was assessed by the committee as an intervention with a positive value contribution for the treatment of moderate-to-severe psoriasis in comparison to any of the alternatives. The drug provides a substantial therapeutical benefits and improves the health results reported by the patients, as it combines a higher level of clearance, rapidity, and persistence with a similar safety and tolerability profile.

Conclusions

Under a methodology with increasing use in the health field, bimekizumab was evaluated as a drug with a high added value for the treatment of moderate-to-severe psoriasis when compared to six different alternatives.

KEYWORDS:

• Psoriasis
• moderate-to-severe
• biologics
• multi-criteria decision analysis
• MCDA
• bimekizumab

Authors contributions

N Zozaya and A Hidalgo participated in the conception and design of the work. N Zozaya, F Abdalla, S Alfonso, J Balea, J Carrascosa, O Delgado, F Dolz, A Garcia-Ruiz, P Herranz, A Manfredi, J Martinez, P Morales de los Rios Luna, L Puig and S Ros have contributed to the acquisition of data. N Zozaya and F Abdalla have analyzed and interpreted the data. F Abdalla has drafted the manuscript, and N Zozaya has substantively reviewed it. All authors have approved the manuscript and have agreed both to be personally accountable for the author’s contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

List of abbreviations

ADA Adalimumab

AEMPS Spanish Medicines and Healthcare Products Agency

BKZ Bimekizumab

EMA European Medicines Agency

EVIDEMEvidence and Value: Impact on DEcision Making

IL Interleukin inhibitors

IXE Ixekizumab

MCDA Multi-Criteria Decision Analysis

MEC Multidisciplinary Experts Committee

PASI Psoriasis Area and Severity Index

PBO Placebo

RIS Risankizumab

SEC Secukinumab

TNF Tumor Necrosis Factor inhibitors

UST Ustekinumab

Data availability statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declaration of interest

N Zozaya, F Abdalla and A Hidalgo are employed by the consultancy firm Weber, which received funding for the development of this project. S Alfonso, J Balea, J Carrascosa, O Delgado, F Dolz, A Garcia-Ruiz, P Herranz, A Manfredi, J Martinez, P Morales de los Rios Luna, L Puig and S Ros received fees from the consultancy firm Weber for the participation in the project. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Supplementary material

Supplemental data for this article can be accessed here

Additional information

Funding

This project was funded by UCB Pharma S.A.